[ad_1]
A woman with advanced breast cancer in Florida can not be cured and was cured two and a half years later of a new treatment that stimulates her immune cells to target the tumor. .
These three patients were treated by the National Cancer Institute team led by Steven Rosenberg, pioneer of immunotherapy and head of the surgical department, who genetically engineered each patient's tumors to find mutations and then test the cancer cells. Recognize the defects, then multiply these cells billions of times in the lab, then re-implant them in patients to attack the tumors.
Rosenberg pointed out that this method is "experimental cell therapy" and that many other patients have not responded to treatment. "These three cases indicate a pattern aimed at targeting a wide range of advanced solid tumors of the internal organs, stomach, esophagus, ovary."
These mutations account for the vast majority of the 600,000 cancer deaths that will occur in US territory this year. "This method depends on mutations, not cancer, and carcinogenic mutations will be its weak point," he said.
Judy Perkins is a 52-year-old construction engineer who lives in Florida. , she was diagnosed with early stage breast cancer and a hysterectomy, after which I learned that the cancer had spread to other parts of her body, that she had had several treatments and that she had finally failed.In 2015, a senior NCI scientist encouraged her to enroll in the experiment.
One of her tumors was surgically removed and had 62 different mutations Researchers then extracted immune cells from malignant clusters, leukocytes, lymphocytes or tumor cells, and found cells that targeted four of these defects.
They then multiplied their numbers to tens of billions, and Perkins underwent chemotherapy first followed by the introduction of immune cells. After five months, the results announced cancer recovery, and Perkins surprised the result and responded that she never expected recovery.
Experiments on one patient or even a small number do not prove that treatment will succeed and affect others.
Perkins treated more than 40 patients with solid tumors spread over the last four years using this method. Most of them went into the experience and had a very limited virtual life, and 15% responded one way or the other. But these answers vary, says Stephanie Goff, a team doctor. Perkins was the exception (as a full beneficiary) and did not require any additional treatment.
"Researchers are trying to find solutions for more appropriate results," said Goff. However, healing in all three cases is an important advance, according to the researchers.
Immunotherapy Patients with advanced melanoma, lung cancer and some other mutations with many mutations had no effect on cancers that start in the organ lining such as epithelial cancers, which contain few mutations.
Other scientists have welcomed the news but with reservations. "The response of a breast cancer patient to Tils was striking," says Carl John, an expert in immunotherapy at the University of Pennsylvania. "Was it one for a million? And how many women will benefit?" "Overtime is crucial, and this article shows vital evidence of the treatment principle and that way you can have a strong impact on the patient, "said Scott Antonia, an immunologist at the Moffitt Cancer Center in Tampa, Florida. .
Melinda Pachini, a former healer living in Montana, believes that this treatment saved her life. In 2009, she was diagnosed with cancer of the bile ducts that spread to the liver while she was 41 years old.
underwent surgery to remove two-thirds of the liver, but after 3 months, the disease appeared in the lungs, various methods of treatment failed, and the NCI test was found online. In 2012, I had my first dose of Tils and the tumors started to shrink.
When tumors began to grow again the following year, another group of cells received more aggressive mutations and the tumors again decreased. In the fall of 2016, she needed more treatment and returned to NCI for another type of immunotherapy. Today, she says that she has few spots in her left lung, which Rosenberg thinks is a scar.
The patient with advanced colon cancer treated by the Rosenberg team in 2015 is Celine Ryan of Michigan. Most of her tumors disappeared after she had had Tils, although one of her lungs got worse and required more surgery.
is still free of cancer today, and on the other hand Rosenberg, the first successful target of a tumor called KRAS, is a mutation associated with colon cancer as well as pancreatic cancer and lung.
Perkins remembers a 3-year-old tumor specialist when she returned to breast cancer in early 2013. During her post-treatment treatment, she became a cancer advocate. breast and went to California to receive a Breast Cancer Coalition training).
Perkins hopes that she will be cured – a word she's afraid to say – but she knows that cancer can come back in the future. Know that most patients with breast cancer are not lucky and that experimental treatments can be very risky.
I contacted Perkins, a South Carolina woman named Janis Satterfield, after reading a flyer that she had written about the NCI test. Satterfield decided to enroll and go to the treatment center in August 2016. But she developed complications and died a few months later.
Her husband, Scott Satterfield, said: "I may have lost my life, but I hope that someone else will benefit from his experience."
- Review: LOUAY HAJ YOUSEF
- Editing: Ahmed Azab
- Source
[ad_2]
Source link
